Margie Hunt

Margie Hunt

Auto-generated profile, based on publicly available information

Margie Hunt

Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2002 in International Journal of Radiation Oncology, Biology, Physics
Verified
Journal Article
Closed access
MZMichael J Zelefsky
Michael J Zelefsky
ZFZvi Fuks
Zvi Fuks
MHMargie Hunt
Margie Hunt
YYYoshiya Yamada
Yoshiya Yamada
CMChristine Marion
Christine Marion
SLSteven A Leibel
Steven A Leibel

1 March 2008 in International Journal of Radiation Oncology, Biology, Physics
Verified
Journal Article
Closed access
MZMichael J. Zelefsky
Michael J. Zelefsky
ELEmily J. Levin
Emily J. Levin
MHMargie Hunt
Margie Hunt
YYYoshiya Yamada
Yoshiya Yamada
ASAlison M. Shippy
Alison M. Shippy
HAHoward I. Amols
Howard I. Amols

1 September 2001 in Journal of Urology
Verified
Journal Article
Closed access
MZMichael J. Zelefsky
Michael J. Zelefsky
ZFZvi Fuks
Zvi Fuks
MHMargie Hunt
Margie Hunt
HLHenry J. Lee
Henry J. Lee
DLDanna Lombardi
Danna Lombardi
SLSteven A. Leibel
Steven A. Leibel

1 September 2012 in International Journal of Radiation Oncology, Biology, Physics
Verified
Journal Article
Closed access
MZMichael J. Zelefsky
Michael J. Zelefsky
MKMarisa Kollmeier
Marisa Kollmeier
BCBrett Cox
Brett Cox
AFAnthony Fidaleo
Anthony Fidaleo
DSDahlia Sperling
Dahlia Sperling
MHMargie Hunt
Margie Hunt

1 June 2000 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
MZMichael J Zelefsky
Michael J Zelefsky
ZFZvi Fuks
Zvi Fuks
LHLaura Happersett
Laura Happersett
HLHenry J Lee
Henry J Lee
CLC.CLifton Ling
C.CLifton Ling
SLSteven A Leibel
Steven A Leibel

1 October 2006 in Journal of Urology
Verified
Journal Article
Closed access
MZMichael J. Zelefsky
Michael J. Zelefsky
HCHeather Chan
Heather Chan
MHMargie Hunt
Margie Hunt
YYYoshiya Yamada
Yoshiya Yamada
ASAlison M. Shippy
Alison M. Shippy
HAHoward Amols
Howard Amols
We report on the long-term results and late toxicity outcomes of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. Between 1996 and 2000 a total of 561 patients with clinically localized prostate cancer were treated with intensity modulated radiation therapy. All patients were treated to a dose of 81 Gy prescribed to the planning target volume. Prostate specific antigen relapse was defined according to the American Society for Therapeutic Radiology and Oncology consensus and Houston definitions (absolute nadir plus 2 ng/ml dated at the call). Median followup was 7 years (range 5 to 9). The 8-year actuarial PSA relapse-free survival rates for patients in favorable, intermediate and unfavorable risk groups according to the American Society for Therapeutic Radiology and Oncology definition were 85%, 76% and 72%, respectively (p <0.025). The 8-year actuarial prostate specific antigen relapse-free survival rates for patients in favorable, intermediate and unfavorable risk groups according to the Houston definition were 89%, 78% and 67%, respectively (p = 0.0004). The 8-year actuarial likelihood of grade 2 rectal bleeding was 1.6%. Three patients (0.1%) experienced grade 3 rectal toxicity requiring either 1 or more transfusions or a laser cauterization procedure. No grade 4 rectal complications have been observed. The 8-year likelihood of late grade 2 and 3 (urethral strictures) urinary toxicities were 9% and 3%, respectively. Among patients who were potent before intensity modulated radiation therapy, erectile dysfunction developed in 49%. The cause specific survival outcomes for favorable, intermediate and unfavorable risk cases were 100%, 96% and 84%, respectively. These long-term results confirm our previous observations regarding the safety of high dose intensity modulated radiation therapy for clinically localized prostate cancer. Despite the application of high radiation doses, the incidence of rectal bleeding at 8 years was less than 2%. Despite the increased conformality of the dose distribution associated with intensity modulated radiation therapy, excellent long-term tumor control outcomes were achieved.